Dr Ninib Baryawno received his PhD diploma at Karolinska Institutet under the supervision of associate professor John Inge Johnsen and professor Per Kogner. His thesis work focused on developing novel therapeutics based on better biological understanding of the childhood brain tumor medulloblastoma. A disorder of development, arising mostly in the cerebellum during embryogenesis and is largely dictated by events in stem cell regulatory signaling pathways. His research was published as a thesis “New Potential Targets in Medulloblastoma Therapy – Studies on Cellular Mechanisms and Mediators”, and defended in February 2010.
It was the interest in stem cell based approaches to disease that brought Dr Baryawno together with professor David Scadden at Harvard University and Massachusetts General Hospital in 2011. Dr Baryawno was a postdoctoral fellow in the Scadden lab until 2017 where he applied single-cell RNA-sequencing to study how the hematopoietic stem cell niche supports outgrowth of murine leukemia and human bone metastases.
Dr Baryawno became Assistant professor at Karolinska Institutet in January 2018.
The lab focus is to solve problems that limit the ability of cancer therapy to be used more effectively against deadly forms of pediatric cancers and adult cancers. We focus our research on pediatric tumors of the nervous system such as neuroblastoma and medulloblastoma, and bone metastases from different tumor origin.
Our research is balanced by a commitment to the value of basic and translational research. This effort is based on the integrated approach of single-cell technologies, computational modeling, and functional preclinical testing, directed at understanding the role of the tumor microenvironment in cancer development, tumor cell dissemination and cancer resistance.
Read more about our work here.
2001-2005, Biomedicine programme, Karolinska Institutet.
2005-2010, PhD training, Karolinska Institutet.
2011-2017, Postdoc fellowship, Harvard University/Massachusetts General Hospital.